DrugPatentWatch Database Preview

Arbor Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ARBOR PHARMS LLC, and when can generic versions of ARBOR PHARMS LLC drugs launch?

ARBOR PHARMS LLC has twenty-two approved drugs.

There are nineteen US patents protecting ARBOR PHARMS LLC drugs.

There are two hundred and sixty-eight patent family members on ARBOR PHARMS LLC drugs in forty-two countries and twenty-six supplementary protection certificates in fourteen countries.

Summary for Arbor Pharms Llc

International Patents:	268
US Patents:	19
Tradenames:	23
Ingredients:	15
NDAs:	22

Drugs and US Patents for Arbor Pharms Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Arbor Pharms Llc	SKLICE	ivermectin	LOTION;TOPICAL	202736-001	Feb 7, 2012		RX	Yes	Yes	8,927,595
Arbor Pharms Llc	BIDIL	hydralazine hydrochloride; isosorbide dinitrate	TABLET;ORAL	020727-001	Jun 23, 2005		RX	Yes	Yes	6,784,177
Arbor Pharms Llc	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes	8,026,279		Y	Y
Arbor Pharms Llc	EDARBI	azilsartan kamedoxomil	TABLET;ORAL	200796-002	Feb 25, 2011		RX	Yes	Yes	7,572,920		Y

Expired US Patents for Arbor Pharms Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Arbor Pharms Llc	EDARBYCLOR	azilsartan kamedoxomil; chlorthalidone	TABLET;ORAL	202331-002	Dec 20, 2011	5,736,555
Arbor Pharms Llc	EDARBI	azilsartan kamedoxomil	TABLET;ORAL	200796-002	Feb 25, 2011	5,958,961
Arbor Pharms Llc	EDARBYCLOR	azilsartan kamedoxomil; chlorthalidone	TABLET;ORAL	202331-002	Dec 20, 2011	5,583,141
Arbor Pharms Llc	EDARBI	azilsartan kamedoxomil	TABLET;ORAL	200796-002	Feb 25, 2011	5,736,555

Paragraph IV (Patent) Challenges for ARBOR PHARMS LLC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Lotion	0.5%		2017-09-01

Non-Orange Book US Patents for Arbor Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,150,503	Crystalline form of .gamma.-aminobutyric acid analog
7,423,169	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
8,906,412	GABA analog prodrug sustained release oral dosage forms
7,790,708	Prodrugs of GABA analogs, compositions and uses thereof

International Patents for Arbor Pharms Llc Drugs

Country	Document Number	Estimated Expiration
Taiwan	200902089
South Africa	200309679
Canada	2666365
Malaysia	142807

Supplementary Protection Certificates for Arbor Pharms Llc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
90016-3	Sweden		PRODUCT NAME: AZILSARTANMEDOXOMIL OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV, INKLUDERANDE KALIUMSALT; REG. NO/DATE: EU/1/11/735/001 20111207
15/046	Ireland		PRODUCT NAME: IVERMECTIN; NAT REGISTRATION NO/DATE: PA0590/028/001 20150424; FIRST REGISTRATION NO/DATE: MA117/01101 20150402
/2015	Austria		PRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402
90036	Netherlands		PRODUCT NAME: CARMUSTINE; NAT. REGISTRATION NO/DATE: RVG 24056 19990809; FIRST REGISTRATION: FR 561 907-5 19981210

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Arbor Pharms Inc
• Arbor Pharms Llc